Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;28(8):4158-4170.
doi: 10.1245/s10434-021-09871-6. Epub 2021 Apr 7.

The Landmark Series: Hilar Cholangiocarcinoma

Kevin C Soares  1   2 , William R Jarnagin  3   4
Affiliations
Review

The Landmark Series: Hilar Cholangiocarcinoma

Kevin C Soares et al. Ann Surg Oncol. 2021 Aug.

Abstract

Hilar cholangiocarcinoma (HC) is a rare and highly aggressive biliary tract neoplasm. As such, the data driving the management of this disease generally are not based on prospective clinical trial data but rather consist of retrospective experiences and limited level 1 data. Surgical resection offers the best chance of a long-term survival, but local and distant recurrences are common. This report presents landmark articles that form the basis of preoperative, operative, and adjuvant strategies for HC.

PubMed Disclaimer

Conflict of interest statement

Disclosures: The authors have no conflicts of interest

Figures

Figure 1:
Figure 1:
Bile duct cancer adjuvant trial (A) flow chart and Kaplan-Meier estimates of (B) overall survival (p=0.997) and (C) relapse-free survival (p=0.72)
Figure 2:
Figure 2:
SWOG S0809 survival plots. Overall survival of the entire cohort (A) and stratified by resection margin (B) of extrahepatic bile duct cancer and gallbladder cancer patients who receive adjuvant chemotherapy and radiation.
See this image and copyright information in PMC

References

    1. Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN. Hilar cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015;17(8):691–699. - PMC - PubMed
    1. Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–588. - PMC - PubMed
    1. Lidsky ME, Jarnagin WR. Surgical management of hilar cholangiocarcinoma at Memorial Sloan Kettering Cancer Center. Ann Gastroenterol Surg. 2018;2(4):304–312. - PMC - PubMed
    1. Groot Koerkamp B, Wiggers JK, Allen PJ, et al. Recurrence Rate and Pattern of Perihilar Cholangiocarcinoma after Curative Intent Resection. J Am Coll Surg. 2015;221(6):1041–1049. - PMC - PubMed
    1. Nakeeb A, Pitt HA. Radiation therapy, chemotherapy and chemoradiation in hilar cholangiocarcinoma. HPB (Oxford). 2005;7(4):278–282. - PMC - PubMed